Emerging markets are growing in size and in importance for drug developers. Countries outside the traditional markets of the United States, Europe, and Japan are revamping their regulatory and legal systems and reforming their healthcare systems, and they are expected to contribute more to the global pharmaceutical industry.
The seven “pharmerging” markets that IMS Health tracks — Brazil, China, India, Mexico, Russia, South Korea, and Turkey — will contribute more than half of global market growth in 2009 and sustain an average of 40% contribution through 2013.
China, which is currently the sixth-largest pharmaceutical market, will become…
Research & Development Around the World
Pharmaceutical Market Access 2010: Strategic Developments Impacting the US, EU, and Emerging Markets
Solving the Patient Education Puzzle
CRO Provider Opportunities Emerge in China
Global R&D Stats
Factors to Consider in Emerging Markets
Forecasted Sales* in Key Markets
Mistakes in Location Selection
Experts on this topic
Sam Azoulay. Senior VP, Medical & Development, Emerging Markets Business Unit, Pfizer Inc., a biopharmaceutical company. For more information, visit pfizer.com.
Paul Boni. Chief Research Officer, Grail Research, a global research and decision support firm. For more information, visit grailresearch.com.
Carolyn Buck Luce. Global Pharmaceutical Sector Leader, Ernst & Young, which provides assurance, tax, transaction, and advisory services. For more information, visit ey.com.
Neil Campbell. Chairman and CEO, Mosaigen Corp., a global healthcare and ICT technology development corporation. For more information, visit mosaigen.com. Mr. Campbell is also Managing Director, Tranziger Ltd., which offers strategic
transaction advisory and execution services.
Todd Clark. President, Value of Insight Consulting Inc., a life-sciences advisory and publishing company. For more information, visit voiconsulting.com.
Terri Cooper, Ph.D. Principal, Deloitte Consulting LLP, Life Sciences Industry Group, which serves customers in aviation, consumer products and services, energy, financial services, healthcare, manufacturing, and technology. For more information, visit deloitte.com/lifesciences.
Matthew Eberhart. Global Business Development Leader, Quintiles Consulting, which works with biopharmaceutical and medical device companies by combining data analytics and practical, evidence-based insights. For more information, visit quintiles.com/consulting.
Patrick Lindsay. Executive VP, United BioSource Corp., which is a global pharmaceutical services organization that helps emerging and established life-sciences companies gather and analyze evidence to develop and commercialize their medical products. For more information, visit unitedbiosource.com.
Rudiger Mees. CEO, Unithink, which provides easy and accessible e-clinical technologies to pharmaceutical and biotech companies across the globe. For more information, visit unithink.com.
Michael O’Connell. Director of Life Sciences, Tibco Spotfire Inc., a provider of enterprise analytics software for
next-generation business intelligence. For more information, visit spotfire.tibco.com.
Umakanta Sahoo, Ph.D. Executive Director, Asia Pacific, Chiltern, which is a global contract research organization with experience conducting and staffing Phase I to Phase IV clinical trials across a broad therapeutic range. For more information, visit chiltern.com.
Mark Weinstein. CEO, BioClinica Inc., a global provider of clinical trials services, helping to support drug and product development efforts through all phases of the clinical trial process. For more information, visit bioclinica.com or e-mail email@example.com.
Claire R. Wynters. Business Development Associate, Criterium Inc., a global, full-service, and technology-driven contract research organization. For more information, visit criteriumusa.com.